Sign in

CIK 0001936258 · Large accelerated filer

NewAmsterdam Pharma Co N.V.

Sign in to watch
Ticker
NAMS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
Netherlands
Entity type
operating
Phone
35 206 2971
Business address
GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
Former names
NewAmsterdam Pharma Co B.V.

Securities

  • NAMS Ordinary Shares Nasdaq
  • NAMSW Warrant Nasdaq
Open-market buys, last 90 days
$226,500
in 1 filing
Open-market sales, last 90 days
$4,661,919
in 3 filings, $4.6M under 10b5-1 plans

Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Kastelein Johannes Jacob Pieter −$4.6M Chief Scientific Officer sold 72% of stake
  2. Davidson Michael H. +$227K Chief Executive Officer 1 filing
  3. Smither John W −$41K Director sold 15% of stake
Date Insider Transaction Shares Price Value Owned after
2026-01-20 Somaiya Mayur Ian Chief Financial Officer Sale 10b5-1 −39,712 $31.78 $1.3M 77,986
2026-01-20 Somaiya Mayur Ian Chief Financial Officer Sale 10b5-1 −19,604 $32.38 $635K 58,382
2026-01-20 Somaiya Mayur Ian Chief Financial Officer Option exercise · Option (Right to Buy) 10b5-1 −60,216 702,598
2026-01-07 van der Kamp Hilde Johanna Director Grant or award +3,400 10,360
2026-01-07 van der Kamp Hilde Johanna Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 Gulfo Adele M. Director Grant or award +3,400 14,260
2026-01-07 Gulfo Adele M. Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 Davidson Michael H. Chief Executive Officer Sale 10b5-1 −11,582 378,859
2026-01-07 Davidson Michael H. Chief Executive Officer Grant or award 10b5-1 +81,000 459,859
2026-01-07 Davidson Michael H. Chief Executive Officer Grant or award · Option (right to buy) 10b5-1 +364,000 364,000
2026-01-07 Lewis William Director Grant or award +3,400 10,360
2026-01-07 Lewis William Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 Smither John W Director Grant or award +3,400 10,360
2026-01-07 Smither John W Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 McKenna Mark C. Director Grant or award +3,400 10,360
2026-01-07 McKenna Mark C. Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 LANGE LOUIS G Director Grant or award +3,400 10,360
2026-01-07 LANGE LOUIS G Director Grant or award · Option (right to buy) +15,300 15,300
2026-01-07 Kastelein Johannes Jacob Pieter Chief Scientific Officer Grant or award 10b5-1 +25,500 98,981
2026-01-07 Kastelein Johannes Jacob Pieter Chief Scientific Officer Grant or award · Option (right to buy) 10b5-1 +115,000 115,000

Page 5 of 15 · 300 trades